Fate Therapeutics (FATE) AI Stock Analysis

• Market Cap: $121.12M
• Dividend Yield: N/A
• Average Volume (3M): 2.28M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.97
• Revenue Growth: -46.92%
• EPS Growth: 20.26%
• Country: US
• Employees: 181
• Sector: N/A
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -0.27
• Shares Outstanding: 115,352,290
• 10 Day Avg. Volume: 1,752,374
• 30 Day Avg. Volume: 2,275,470
• PEG Ratio: 0.00
• Price to Book (P/B): 0.59
• Price to Sales (P/S): 13.76
• P/FCF Ratio: -1.52
• Enterprise Value/Market Cap: 0.11
• Enterprise Value/Revenue: 1.93
• Enterprise Value/Gross Profit: 1.93
• Enterprise Value/Ebitda: -0.10
• 1Y Price Target: $5.29
• Price Target Upside: 451.04% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 9
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: $1.00 ▲(4.17% Upside)

Fate Therapeutics' overall stock score is influenced by significant financial challenges and a concerning valuation, which are partially offset by positive corporate developments. The promising Phase 1 trial results provide a potential growth catalyst, but the company's persistent financial struggles and negative valuation metrics weigh heavily on the score.

Fate Therapeutics Business Overview & Revenue Model

Company Description

Fate Therapeutics, Inc. is a biotechnology company focused on developing innovative cell-based therapies for cancer and immune disorders. The company operates primarily in the regenerative medicine sector, leveraging its proprietary induced pluripotent stem cell (iPSC) platform to create off-the-shelf cellular therapies that are designed to enhance the immune system's ability to combat diseases. Key products in their pipeline include various engineered cell therapies intended for the treatment of hematologic malignancies and solid tumors, as well as applications in hematopoietic cell transplantation and autoimmune diseases.

How the Company Makes Money

Fate Therapeutics generates revenue through a combination of product development collaborations, licensing agreements, and the advancement of its clinical programs. Significant revenue streams include milestone payments from partnerships with pharmaceutical companies, royalties on future sales of licensed products, and potential product sales once therapies receive regulatory approval. The company collaborates with leading organizations in the biopharmaceutical industry to develop and commercialize its therapies, which can provide substantial financial backing and resources while also offering avenues for revenue generation through successful clinical trials and market entry.

Fate Therapeutics Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Fate Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.96
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FATE, the sentiment is Negative. The current price of 0.96 is below the 20-day moving average (MA) of 1.07, below the 50-day MA of 1.22, and below the 200-day MA of 1.13, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 44.75 is Neutral, neither overbought nor oversold. The STOCH value of 22.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FATE.

Fate Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	―	―	―	―	―	―
STTK	54 Neutral	$182.88M	-2.90	-57.84%	―	-84.46%	33.32%
CGEN	52 Neutral	$142.17M	-5.05	-52.95%	―	-88.47%	-1658.33%
FATE	50 Neutral	$121.12M	-0.80	-52.35%	―	-46.92%	20.26%
CRDF	47 Neutral	$162.34M	-3.15	-102.71%	―	-27.29%	16.40%
ONC	43 Neutral	―	―	―	―	―	―
NKTX	39 Underperform	$125.72M	-1.27	-26.69%	―	―	25.84%

Fate Therapeutics Corporate Events

Fate Therapeutics Reports Promising Phase 1 Trial Results

On October 26, 2025, Fate Therapeutics announced promising results from a Phase 1 clinical trial of its FT819 CAR T-cell therapy for systemic lupus erythematosus (SLE), presented at the ACR Convergence 2025. The trial, involving 10 patients, demonstrated significant reductions in disease activity scores and favorable safety profiles, suggesting potential for outpatient treatment and same-day discharge. The company is also advancing its clinical programs with plans for a pivotal study in 2026, aiming to enhance its market position in autoimmune disease treatment.

Fate Therapeutics Appoints New CFO Kamal Adawi

On October 10, 2025, John D. Mendlein and Neelufar Mozaffarian resigned from Fate Therapeutics‘ Board, leading to a reduction in the Board’s size from ten to eight members. Subsequently, on October 13, 2025, Kamal Adawi was appointed as the new Chief Financial Officer, effective October 20, 2025. Adawi, with over 20 years of financial leadership experience in the life sciences industry, is expected to play a crucial role in advancing the company’s financial strategy and supporting its clinical programs, particularly the development of FT819 in systemic lupus erythematosus (SLE).